Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Capital Expenditures (2016 - 2023)

Historic Capital Expenditures for Altimmune (ALT) over the last 14 years, with Q2 2023 value amounting to -$4000.0.

  • Altimmune's Capital Expenditures fell 12105.26% to -$4000.0 in Q2 2023 from the same period last year, while for Sep 2025 it was -$4000.0, marking a year-over-year change of. This contributed to the annual value of $47000.0 for FY2023, which is 6269.84% down from last year.
  • Per Altimmune's latest filing, its Capital Expenditures stood at -$4000.0 for Q2 2023, which was down 12105.26% from $51000.0 recorded in Q1 2023.
  • Altimmune's 5-year Capital Expenditures high stood at $7.7 million for Q2 2021, and its period low was -$4000.0 during Q2 2023.
  • Moreover, its 5-year median value for Capital Expenditures was $44500.0 (2022), whereas its average is $780949.0.
  • In the last 5 years, Altimmune's Capital Expenditures soared by 597270000.0% in 2020 and then tumbled by 12105.26% in 2023.
  • Altimmune's Capital Expenditures (Quarter) stood at $1.0 in 2019, then surged by 10362700.0% to $103628.0 in 2020, then soared by 41.85% to $147000.0 in 2021, then crashed by 74.15% to $38000.0 in 2022, then crashed by 110.53% to -$4000.0 in 2023.
  • Its Capital Expenditures stands at -$4000.0 for Q2 2023, versus $51000.0 for Q1 2023 and $38000.0 for Q4 2022.